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Cannabinoid receptor type 2 (CB2) activation is recently reported to promote proliferation of some types of resident stem cells 
(e.g., hematopoietic stem/progenitor cell or neural progenitor cell). Resident cardiac progenitor cell (CPC) activation and pro-
liferation are crucial for endogenous cardiac regeneration and cardiac repair after myocardial infarction (MI). This study aims 
to explore the role and possible mechanisms of CB2 receptor activation in enhancing myocardial repair. Our results revealed 
that CB2 receptor agonist AM1241 can significantly increase CPCs by c-kit and Runx1 staining in ischemic myocardium as 
well as improve cardiomyocyte proliferation. AM1241 also decreased serum levels of MDA, TNF-α and IL-6 after MI. In ad-
dition, AM1241 can ameliorate left ventricular ejection fraction and fractional shortening, and reduce fibrosis. Moreover, 
AM1241 treatment markedly increased p-Akt and HO-1 expression, and promoted Nrf-2 nuclear translocation. However, PI3K 
inhibitor wortmannin eliminated these cardioprotective roles of AM1241. In conclusion, AM1241 could induce myocardial 
regeneration and improve cardiac function, which might be associated with PI3K/Akt/Nrf2 signaling pathway activation. Our 
findings may provide a promising strategy for cardiac endogenous regeneration after MI.  
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Myocardial infarction (MI) and its complications are the 
leading causes of mortality and morbidity worldwide. Re-
vascularization and medication therapy are unable to recon-
stitute the necrotic myocardium and improve cardiac func-
tion. In recent years, stem-cell therapy emerged as a prom-
ising strategy for patients after MI [1]. Nevertheless, clinical 
applications of exogenous stem-cell therapy are seriously 
hindered because it is time-consuming and costly to isolate 
and expand stem cells, as well as due to poor retention and 
survival capacity after engraftment [2]. Thus, in situ activa-
tion, proliferation and differentiation of endogenous stem 
cells attract significant interest. Under normal conditions, 
multipotent cardiac progenitor cells (CPCs) that are present in 
the mammalian heart maintain homeostasis. Once they re-
ceive some stimulation, such as pharmacological administra-
tion, growth-factor intervention or microRNA regulation, 
these CPCs can be activated in situ to differentiate into car-
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diomyocytes that promote myocardial regeneration [35]. 
The endocannabinoid system, especially the cannabinoid 
receptor-type 2 (CB2 receptor), has been recently reported 
to be involved in cardioprotective effects on MI injury [6]. 
Nevertheless, precise mechanisms have not been elucidated 
clearly. Some studies suggested that cardioprotective roles 
of the CB2 receptor could be partially attributed to an-
ti-inflammation and anti-oxidative stress of the infarcted 
myocardium [7]. Interestingly, Palazuelos et al. [8] revealed 
that CB2-selective agonists promoted neural progenitor cell 
proliferation via activating the PI3K/Akt/mTORC1 signal-
ing pathway. Moreover, Jiang et al. [9] reported that canna-
binoid receptor 2 and its agonists modulated hematopoietic 
stem and progenitor cell mobilization and function. Howev-
er, whether CB2 receptor sensitization could activate CPCs 
in situ and promote myocardial regeneration is still un-
known. 
In the present research, we hypothesized that CB2-   
selective agonists (AM1241) could activate CPCs in situ, 
promoting endogenous regeneration of myocardium and 
cardiac repair after MI, and preliminarily elucidated the 
potential mechanism.  
1  Materials and methods  
1.1  Mice model of myocardial infarction  
C57BL/6 male mice (8-week-old, weighing 2025 g) were 
randomly allocated into the following groups (n=20 each): 
(i) Sham group (Sham), (ii) MI+PBS group (MI), (iii) 
MI+CB2 agonist AM1241 group (MI+AM), (iv) MI+CB2 
agonist AM1241+Wortmannin group (MI+AM+W). 
Mice myocardial infarction was induced by ligation of 
the left anterior descending (LAD) artery [10]. In brief, 
mice were anesthetized with persistent inhaled 2% isoflu-
rane during the operation. A left thoracotomy was per-
formed and the pericardium was opened. The LAD was 
permanently ligated with a 6-0 suture just at the level of the 
left atrium. The ligation was deemed successful when the 
anterior wall of the LV turned pale. For the sham-operated 
mice, open thoracotomy was performed without suturing of 
the LAD. The chest cavity was closed in layers with 4-0 
suture. In the MI+AM group, AM1241 (20 mg kg1 d1; 
Selleck, USA) was intraperitoneally injected into mice for 
seven consecutive days after MI. In the MI+AM+W group, 
Wortmannin (15 μg kg1 d1; Sigma, USA) was injected via 
tail vein for seven consecutive days after MI. All animal 
procedures were conducted in conformity with the National 
Institutes of Health Guide for the Care and Use of Labora-
tory Animals and all experiments were performed in ac-
cordance with the Helsinki Declaration. 
1.2  Echocardiography  
Echocardiography studies were performed with Vevo® 
2100 ultrasound system (VisualSonics, CA) using a 30 MHz 
linear-array ultrasound transducer on baseline (day-1) and 
POD 3, 14 and 28 by a blind investigator. The mice were 
anesthetized with inhaled 2% isoflurane and put in a supine 
position. Both two-dimensional and M-mode images were 
recorded. The left-ventricular end-systolic volume (LVESV) 
and left-ventricular end-diastolic volume (LVEDV) were 
measured to calculate left-ventricular ejection fraction 
(LVEF) and fractional shortening (FS). 
1.3  Masson’s trichrome staining  
The mice were sacrificed and hearts were harvested for his-
tological staining at POD 28. Separate sets of paraf-
fin-embedded tissue sections were stained using Masson’s 
trichrome, resulting in fibrotic (collagen-enriched) areas 
that appeared blue while cellular elements appeared red. For 
10 randomly microscopic fields (200× magnification) of 
each LV, Masson’s trichrome-stained myocardial sections 
were imaged, and the collagen area was calculated as a per-
centage of the total LV myocardial area. This served as an 
estimate of the progression of fibrosis. This calculation was 
performed by an observer blinded to the treatment groups.  
1.4  Immunofluorescence 
CPC and cardiomyocyte proliferation was detected with 
immunostaining for CPC surface marker c-kit, Runx 1 and 
proliferating cell nuclear marker ki67, respectively. Firstly, 
mice were anesthetized seven days after LAD ligation. The 
heart tissue was fixed in 4% paraformaldehyde buffer and  
5 μm thick sections were prepared. Then, tissue sections 
were stained with primary anti-c-kit (1:200, Abcam), anti- 
Runx1 (1:200, Abcam) and anti-ki67 (1:50, Abcam) anti-
bodies, respectively. 4,6-Diamidino-2-phenylindole (DAPI) 
was used to label cell nuclei. Immunofluorescence detection 
was performed with a laser-scanning confocal microscope 
(Olympus FV10i, Japan). The cells that were positive for 
c-kit, Runx 1 and ki67 were counted using the Image-Pro- 
Plus software (version 6.0; National Institutes of Health) in 
at least five high-power fields (HPF, 200×) in the infarct 
and peri-infarct regions, which were randomly selected and 
counted in at least three sections from each animal (n=10 
per group).  
1.5  ELISA assay  
On POD 3, the blood sample (2 mL) was collected from the 
right common carotid artery and placed into Eppendorf 
tubes. After leaving at room temperature for 4 h, the sam-
ples were centrifuged for 20 min (3000×g, 4°C). Aliquots of 
the supernatant were removed and stored at −80°C before 
assay. According to the manufacturer’s instructions, serum 
levels of Malondialdehyde (MDA), TNF-α and IL-6 were 
measured by colorimetric analysis using a spectrophotome-
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ter at a wavelength of 450 nm with the relevant detection 
kits (BIKW, China). 
1.6  Western blot analysis 
Western blot samples were extracted from myocardium on 
POD 7. The heart tissue was then lysed in an ice-cold RIPA 
buffer containing 1% protease inhibitor cocktail (Sigma, 
USA). The sample was centrifuged at 12000×g for 20 min 
at 4°C. The supernatant was transferred, aliquoted and 
stored at 80 °C. After protein concentration measurements 
by the modified Bradford assay (Bio-Rad Laboratories, 
Hercules, USA), the proteins were separated by SDS-PAGE 
electrophoresis, transferred to nitrocellulose membranes and 
probed with primary antibodies against HO-1 (1:1000, 
Abcam, USA), Nrf2 (1:1000, Abcam, USA), p-Akt (1:1000, 
Abcam, USA) overnight at 4°C followed by incubation with 
the corresponding secondary antibodies at room temperature 
for 1 h. The signal was detected using the ECL-Plus reagent 
(GE Healthcare, USA). 
1.7  Statistical analysis 
All statistical analyses were performed by SPSS software 
(Version 15.0, SPSS Inc., USA). All values are expressed as 
means±standard deviation (SD). Statistical differences be-
tween different groups were analyzed using one-way 
ANOVA, two-tailed unpaired t-test or chi-square test. Sta-
tistical significance was set at P<0.05.  
2  Results  
2.1  AM1241 treatment improved cardiac function af-
ter MI 
Echocardiogram was performed to evaluate cardiac function 
at baseline and on post-operative days (POD). The results 
revealed that there was no significant difference among all 
groups at baseline (P>0.05). However, LVEF and FS de-
creased markedly in all groups on POD 3. AM1241 treat-
ment improved LVEF and FS significantly as compared 
with that of the MI group on POD 14 (EF: 43.12%±0.32% 
vs. 37.45%±0.21%, P<0.05; FS: 26.91%±0.13% vs. 23.57% 
±0.22%, P<0.05) and POD 28 (EF: 47.63%±0.37% vs. 
39.82%±0.48%, P<0.05; FS: 28.36%±0.21% vs. 24.01%± 
0.25%, P<0.05) respectively. Wortmannin reversed the 
trend induced by AM1241 (P<0.05) (Figure 1).  
2.2  AM1241 treatment decreased fibrosis after MI 
To detect myocardial fibrosis in the infarcted heart with or 
without the AM1241 treatment, Masson’s trichrome stain-
ing was carried out. Severe fibrosis was observed in the MI 
group, whereas the AM1241 intervention obviously reduced 
fibrosis as compared with that in the MI group (29.4%± 
1.03% vs. 41.36%±1.60%, P<0.05). However, Wortmannin 
eliminated fibrosis-area decrease caused by the AM1241 
administration (39.62%±1.04% vs. 29.4%±1.03%, P<0.05) 
(Figure 2A and B). 
 
 
Figure 1  AM1241 improved cardiac function after myocardial infarction. A, The dynamic changes of cardiac function visualized by in vivo echocardiog-
raphy. B and C, Quantification analysis of ejection fraction (EF) and fractional shortening (FS). *, P<0.05 vs. MI group. 
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Figure 2  AM1241 increased ki67+ positive cells and decreased cardiac fibrosis after MI. A, Masson’s trichrome-stained myocardial sections from a sub-
group of animals at POD 28. B, Comparison of fibrosis areas in all groups. *, P<0.05 vs. MI group; #, P<0.05 vs. MI+AM group. C, Immunohistochemistry 
of Ki67 (green), and DAPI (blue) staining in adjacent infarction areas. D, Comparison of ki67 positive cells in all groups. *, P<0.05 vs. MI group; #, P<0.05 
vs. MI+AM group. Scale bar, 20 μm. 
2.3  AM1241 treatment increased the number of c-kit+ 
and Runx1+ cells and cardiomyocyte proliferation in the 
myocardium after MI 
c-kit and Runx1 are typical markers of cardiac progeni-
tor/stem cells. Thus, c-kit and Runx1 immunofluorescence 
staining was performed to evaluate the number of progeni-
tor/stem cells in the infarcted myocardium after the 
AM1241 treatment. The results revealed that the expression 
of c-kit and Runx1 was elevated significantly in the 
MI+AM group as compared with that in the MI group on 
POD 7 (c-kit: 8.67%±0.72% vs. 4.27%±0.56%, P<0.05; 
Runx1: 9.92%±0.77% vs. 5.54%±0.68%, P<0.05). However, 
Wortmannin eliminated AM1241-induced c-kit and Runx1 
up-regulation (c-kit: 4.47%±0.38% vs. 8.67%±0.72%, 
P<0.05; Runx1: 6.30%±0.55% vs. 9.92%±0.77%, P<0.05) 
(Figure 3).  
To detect proliferating cardiomyocytes, heart sections 
were immunostained with ki67. Interestingly, AM1241 fur-
ther raised the number of ki67+ cardiomyocytes in compar-
ison with the MI group on POD 7 (35.32%±2.03% vs. 
13.14%±1.48%, P<0.05). Wortmannin reversed the increase 
of ki67+ cardiomyocytes in the infarcted heart caused by  
the AM1241 administration (19.08%±1.72% vs. 35.32%± 
2.03%, P<0.05) (Figure 2C and D). 
2.4  AM1241 treatment decreased MDA, TNF-α and 
IL-6 levels in the infarcted myocardium 
MDA caused by oxidative damage serves as a biomarker of 
cardiac oxidative stress injury. Thus, we detected serum 
concentration of MDA to reflect oxidative stress in myocar-
dium with or without the AM1241 administration. The data 
showed that MI significantly increased MDA levels 
(9.34±0.59 nmol mL1 vs. 4.40±0.71 nmol mL1, P<0.05) in 
comparison with the sham group. Moreover, the AM1241 
administration significantly decreased MDA levels as com-
pared with those in the MI group (6.57±0.42 nmol mL1 vs. 
9.34±0.59 nmol mL1, P<0.05) (Figure 4A).  
Next, we explored the MI-induced inflammation by as-
sessing the levels of inflammatory cytokines TNF-α and 
IL-6. The ELISA analysis revealed that MI led to significant 
increases in TNF-α and IL-6, as compared with those in the 
sham group (TNF-α: 19.10±0.85 pg mL1 vs. 10.34±1.15 pg 
mL1, P<0.05; IL-6: 16.53±0.63 pg mL1 vs. 8.33±0.60 pg 
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Figure 3  Effects of AM1241 on cardiac progenitor cell activation in vivo after myocardial infarction. A, Immunohistochemistry of c-kit (Green) and DAPI 
(Blue) staining in adjacent infarction areas. B, Comparison of c-kit positive cells in all groups. *, P<0.05 vs. the MI group; #, P<0.05 vs. MI+AM group. C, 
Immunohistochemistry of Runx1 (red) and DAPI (blue) staining in adjacent infarction areas. D, Comparison of Runx1 positive cells in all groups. *, P<0.05 
vs. MI group; #, P<0.05 vs. MI+AM group. Scale bar, 20 μm. 
mL1, P<0.05). However, AM1241 markedly decreased the 
serum levels of TNF-α and IL-6 induced by MI (TNF-α: 
14.05±1.12 pg mL1 vs. 19.10±0.85 pg mL1, P<0.05; IL-6: 
13.21±0.92 pg mL1 vs. 16.53±0.63 pg mL1, P<0.05). 
Wortmannin could reverse this trend (Figure 4B and C). 
2.5  AM1241 treatment increased Akt phosphorylation, 
Nrf2 nuclear translocation and HO-1 expression 
The PI3K/Akt/Nrf-2 signaling pathway was recently found 
to be related to resistance to oxidative stress and scavenging 
oxygen-free radicals. In our study, we intended to investi-
gate whether AM1241 plays anti-oxidant and anti-     
inflammation roles through modulating the PI3K/Akt/ Nrf-2 
signaling pathway. The Western blot results showed that the 
p-Akt and HO-1 expression was significantly elevated in the 
AM1241 group as compared with that in the MI group 
(P<0.05). Meanwhile, the Nrf-2 levels in the nuclear protein 
were also markedly increased in the AM1241 group as 
compared to that in the MI group (P<0.05). These data in-
dicated that AM1241 increased Akt phosphorylation, Nrf2 
nuclear translocation and HO-1 expression in the infarcted 
myocardium, whereas Wortmannin blocked these effects of 
AM1241 (P<0.05) (Figure 5). 
3  Discussion  
In the present study, we found that selective CB2 agonist 
AM1241 could improve cardiac function and myocardial 
fibrosis after MI, which was related to activation of resident 
CPCs and promotion of endogenous cardiac regeneration. 
Furthermore, our study revealed that AM1241 ameliorated 
adverse oxidative stress and inflammation milieu in in-
farcted heart through up-regulating the PI3K/Akt/Nrf-2 
signal pathway. 
The endocannabinoid system comprises two major 
membrane receptors (CB1 and CB2), the endogenous lig-
ands and specific enzymes for their degradation and inacti-
vation. The CB1 receptor is mainly located in the central 
nervous system, while the CB2 receptor is predominantly  
expressed in peripheral tissue and cells, such as lympho-
cytes, neutrophils and cardiomyocytes [8,1113]. In addi-
tion to immunomodulatory and anti-inflammation properties, 
the CB2 receptor activation has been recently shown to 
promote myocyte survival and to attenuate ischemia/  
reperfusion injury in cardiac tissue [14]. Our echocardiog-
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Figure 4  AM1241 decreased serum levels of LDH, TNF-α and IL-6 levels. AC, Serum levels of LDH, TNF-α and IL-6 were measured by ELISA. *, 
P<0.05 vs. MI group; #, P<0.05 vs. MI+AM group.  
 
Figure 5  The protein expression of phosphorylation of Akt (p-Akt), Nrf2, HO-1 in myocardium was determined by Western blotting. Protein expression 
was quantified by the relative optical density ratio of p-Akt (A), Nrf-2 (B) and HO-1 (C). *, P<0.05 vs. MI group; #, P<0.05 vs. MI+AM group. 
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Figure 6  Proposed scheme for the mechanisms of anti-oxidative stress by 
CB2 agonist AM1241. 
raphy and histology data demonstrated that AM1241 could 
significantly improve cardiac function. Furthermore, it also 
reduced fibrosis and prevented infarcted myocardium re-
modeling. These results were consistent with other previous 
reports [7]. With regard to precise mechanisms of cardiac 
protective roles of the CB2 receptor, some studies attributed 
them to anti-inflammatory and antioxidant properties. Nev-
ertheless, the mechanisms by which CB2 receptor activation 
promotes cardiac repair and functional recovery through 
anti-inflammatory and antioxidant properties remain un-
clear. 
Theoretically, it is somewhat controversial whether en-
dogenous cardiac regeneration is the best route to cardiac 
repair to replace lost cardiomyocytes after MI [15]. Resi-
dent cardiac progenitor or stem cells are the major sources 
giving rise to regenerated cardiomyocytes [5]. However, the 
isolation, expansion and transplantation of CPCs are slow, 
expensive and low-quality, which inhibits their application 
in treating chronic heart failure after MI [16]. Therefore, it 
is necessary to provide new strategies to activate CPCs with 
cardiac regenerative potential in situ by drug, cytokine, or 
growth factor intervention [2]. Interestingly, the CB2 re-
ceptor activation was shown to promote activation and pro-
liferation of some types of endogenous stem cells (e.g., 
hematopoietic stem/progenitor cells and neural progenitor 
cells) in vivo [8,9]. However, it is still unknown whether the 
CB2 receptor sensitization can activate endogenous cardiac 
progenitor cells in situ, which needs to be further investi-
gated.  
Our study demonstrated that AM1241 significantly 
raised expression of c-kit and Runx1 (typical progenitor cell 
markers) in the infarcted heart on POD 7. These results 
suggested that the CB2 receptor activation could accelerate 
resident CPC proliferation in vivo. Additionally, it has been 
demonstrated that the resident CPC activation is able to 
promote myocyte self-renewal and heart-tissue repair after 
MI [15]. In the present study, we immunostained heart tis-
sue sections with cell proliferation marker ki-67 and found 
that the AM1241 administration increased ki67 expression 
in myocardium after MI, which indicated that selective CB2 
agonist was capable of promoting cardiomyocyte regenera-
tion and proliferation post-MI. Moreover, this increase of 
resident CPC activation and cardiomyocyte regeneration 
induced by selective CB2 agonist was probably related to 
the reduction of fibrotic area and enhancement in cardiac 
performance. 
It was reported that CPCs that maintain homeostasis in a 
normal heart can be activated by pharmaceutical interven-
tion, microRNA regulators or supporting cell stimulation 
after MI or heart failure to replenish injured or dead cardi-
omyocytes [2]. However, most of the CPCs may gradually 
decrease and be unable to play sustained roles, which be-
comes a major challenge to clinical application of myocar-
dial regeneration therapy [17]. It was recently recognized 
that stem cell niches in vivo affected local CPC activation 
and function through inflammatory and growth cytokines 
secreted by cell neighbors [16]. Modulating the inflamma-
tory response and oxidative stress in the infarcted myocar-
dium to a moderate extent will provide a more suitable mi-
croenvironment for the CPC activation, proliferation and 
differentiation. In this study, we detected MDA, TNF-α and 
IL-6 levels in the infarcted heart with or without CB2 ago-
nist administration, and observed that the CB2 agonist 
markedly decreased MDA, TNF-α and IL-6 levels in vivo. 
This indicated that CB2 receptor activation could inhibit 
inflammatory response and oxidative stress injury in myo-
cardium, which improves cardiac post-ischemic microenvi-
ronment and benefits CPC activation and proliferation. 
Next, it is necessary to investigate related mechanisms 
that may explain the anti-inflammation and anti-oxidant 
properties of the CB2 receptor activation. It is well known 
that Nrf2 is a key component for protecting against oxida-
tive stress injury [18]. Under normal conditions, Keap1 
combines with Nrf2 in the cytoplasm. Oxidative stress 
stimulus can disrupt the Nrf2/Keap1 complex and induce 
the translocation of Nrf2 into the nucleus. Nrf2 then binds 
to ARE (antioxidant-response element), which eventually 
results in increased expression of antioxidant genes such as 
heme oxygenase-1 (HO-1) and glutathione synthetic en-
zyme to resist oxidative stress injury [19]. Our Western blot 
results indicated that the CB2 receptor activation induced an 
increase of Akt phosphorylation, Nrf2 nuclear translocation 
and HO-1 expression, accompanied by cardiac function 
improvement, fibrosis decrease and CPC activation.  
To further identify whether selective CB2 agonist plays 
cardiac protective roles via this signal cascade, we exam-
ined the effects of PI3K inhibitor Wortmannin on the in-
farcted heart in vivo after CB2 agonist administration. We 
found that Wortmannin cancelled the effects of the CB2 
agonist including improving cardiac function enhancement, 
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decreasing fibrotic area, reducing inflammatory cytokine 
secretion and oxidative stress. Additionally, the Wortman-
nin intervention also reversed up-regulation of c-kit, Runx1 
and ki-67 expression caused by the CB2 receptor activation. 
These data illustrated that the treatment with PI3K inhibitor 
Wortmannin could inhibit the CB2 agonist-induced CPC 
activation and cardiomyocyte self-renewal after MI.  
Finally, we observed that the Wortmannin treatment also 
suppressed Akt phosphorylation, Nrf2 nuclear translocation 
and HO-1 expression. Thus, the CB2 receptor activation 
promoted endogenous cardiac regeneration after MI at least 
partially via the PI3K/Akt/Nrf2 signaling pathway. 
In conclusion, we illustrated for the first time that the 
CB2 receptor activation improved cardiac function and re-
pair after MI through accelerating endogenous cardiac re-
generation, which was related to ameliorating the cardiac 
post-ischemic microenvironment via modulating the PI3K/ 
Akt/Nrf2 signaling pathway. 
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